Related Experiment Video
Updated: May 2, 2026

Myelin Oligodendrocyte Glycoprotein MOG35-55 Induced Experimental Autoimmune Encephalomyelitis EAE in C57BL/6 Mice
Published on: April 15, 2014
Neoehrlichiosis associated with ocrelizumab in a patient with multiple sclerosis: A case report
Raja Majid Afzal1, Jeppe Romme Christensen2, Rosa Maja Møhring Gynthersen1
1Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
Objective:
To describe a case of neoehrlichiosis, an emerging opportunistic tick-borne infection, in a patient with multiple sclerosis (MS) treated with ocrelizumab.
Methods:
This is a case study.
Results:
Our patient developed clinical infection over several months while on ocrelizumab and was ultimately diagnosed with neoehrlichiosis, caused by the bacteria Neoehrlichia mikurensis. Resolution of symptoms began within a few days after the initiation of antibiotic treatment.
Conclusion:
We describe the first probable case of ocrelizumab-associated neoehrlichiosis in a patient with MS. Clinicians should be aware of this potentially debilitating and life-threatening infection in patients receiving CD20-depleting therapy.
Insights
This case study reports the first probable instance of Neoehrlichia mikurensis infection in a multiple sclerosis patient undergoing ocrelizumab treatment. Early antibiotic intervention led to symptom resolution, highlighting the need for clinical awareness.
Area of Science:
- Infectious Diseases
- Immunology
- Neurology
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Ocrelizumab is a CD20-depleting antibody used for treating MS, which can increase susceptibility to opportunistic infections.
- Neoehrlichiosis is an emerging tick-borne bacterial infection caused by Neoehrlichia mikurensis.
Observation:
- A patient with MS treated with ocrelizumab developed a prolonged clinical illness over several months.
- The patient was ultimately diagnosed with neoehrlichiosis, a rare opportunistic infection.
Findings:
- The diagnosis of neoehrlichiosis was confirmed in the MS patient on ocrelizumab therapy.
- Symptoms of neoehrlichiosis began to resolve within days of initiating antibiotic treatment.
Implications:
- This case represents the first probable instance of ocrelizumab-associated neoehrlichiosis in an MS patient.
- Clinicians must consider neoehrlichiosis in patients with MS on CD20-depleting therapies, as it can be severe and life-threatening.
- Awareness of this infection is crucial for timely diagnosis and management in immunocompromised patients.
More Related Videos
Related Concept Videos
Arboviral Encephalitis
Cytomegalovirus Disease
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology
Multiple Sclerosis l: Introduction
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

